Biotech News
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update
investors.humacyte.com2026-05-13 11:12 EST
- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer - - First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million in 2025 - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and